Protein inhibitor of activated STAT xα depresses cyclin D and cyclin D kinase, and contributes to the inhibition of osteosarcoma cell progression

Wang,Junjie; Ni,Jiangdong; Yi,Shuai; Song,Deye; Ding,Muliang

doi:10.3892/mmr.2015.4705

Protein inhibitor of activated STAT xα depresses cyclin D and cyclin D kinase, and contributes to the inhibition of osteosarcoma cell progression

Authors:
- Junjie Wang
- Jiangdong Ni
- Shuai Yi
- Deye Song
- Muliang Ding
View Affiliations

Affiliations: Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China, Department of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China
Published online on: December 22, 2015 https://doi.org/10.3892/mmr.2015.4705
Pages: 1645-1652

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have shown that protein inhibitor of activated STAT (PIAs)xα is crucial in protein sumoylation and is associated with cancer cell progression. However, the mechanism underlying the inhibitory effect on cancer cells, which may assist in developing novel treatment strategies in cancer remains to be elucidated. In present study, the expression levels of PIAsxα from tissue samples of osteosarcoma and adjacent tissues from 25 patients were analyzed using reverse transcription‑quantitative polymerase chain reaction, western blot and immunohistochemical analyses. In addition, techniques using an overexpression vector and small interfering (si)RNAs were used to examine the effect of PIAsxα on osteosarcoma cells. Finally, using xenograft U2‑OS osteosarcoma cells overexpressing PIAsxα, the effect of PIAsxα on osteosarcoma formation was determined. The results revealed low expression of PIAsxα in osteosarcoma tissues. In addition, following overexpression of PIAsxα, the apoptotic rates were significantly increased. The rate of G2/M arrest was at the highest level in the overexpression group, compared with other groups assessed. Furthermore, the expression levels of cyclin D1 and cyclin D3 were inhibited following PIAsxα increase, indicating the repressive effects of PIAsxα on cell cycle. Accordingly, cyclin D kinase (CDK) genes, including CDK4, CDK6 and CDK8, increased markedly following treatment with PIAsxα siRNAs. The expression levels of CDK4, CDK6 and CDK8 decreased significantly in the overexpression group, compared to the other groups. Furthermore, high expression levels of PIAsxα inhibited tumor formation in a nude mouse model. Taken together, these findings provide evidence for the effects of PIAsxα and its mechanism on osteosarcoma progression, which offers novel insight into sumoylation and the cell cycle in osteosarcoma.

View Figures

View References

1	Geiss-Friedlander R and Melchior F: Concepts in sumoylation: A decade on. Nat Rev Mol Cell Biol. 8:947–956. 2007. View Article : Google Scholar : PubMed/NCBI
2	Yeh ET: SUMOylation and De-SUMOylation: Wrestling with life's processes. J Biol Chem. 284:8223–8227. 2009. View Article : Google Scholar :
3	Saitoh H and Hinchey J: Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem. 275:6252–6258. 2000. View Article : Google Scholar : PubMed/NCBI
4	Johnson ES: Protein modification by SUMO. Annu Rev Biochem. 73:355–382. 2004. View Article : Google Scholar : PubMed/NCBI
5	Owerbach D, McKay EM, Yeh ET, Gabbay KH and Bohren KM: A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun. 337:517–520. 2005. View Article : Google Scholar : PubMed/NCBI
6	Mukhopadhyay D and Dasso M: Modification in reverse: The SUMO proteases. Trends Biochem Sci. 32:286–295. 2007. View Article : Google Scholar : PubMed/NCBI
7	Cheng J, Wang D, Wang Z and Yeh ET: SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol. 24:6021–6028. 2004. View Article : Google Scholar : PubMed/NCBI
8	Cheng J, Bawa T, Lee P, Gong L and Yeh ET: Role of desumoylation in the development of prostate cancer. Neoplasia. 8:667–676. 2006. View Article : Google Scholar : PubMed/NCBI
9	Wang Q, Xia N, Li T, Xu Y, Zou Y, Zuo Y, Fan Q, Bawa-Khalfe T, Yeh ET and Cheng J: SUMO-specific protease 1 promotes prostate cancer progression and metastasis. Oncogene. 32:2493–2498. 2013. View Article : Google Scholar
10	Zhong S, Salomoni P and Pandolfi PP: The transcriptional role of PML and the nuclear body. Nat Cell Biol. 2:E85–E90. 2000. View Article : Google Scholar : PubMed/NCBI
11	Moschos SJ and Mo YY: Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis. J Mol Histol. 37:309–319. 2006. View Article : Google Scholar : PubMed/NCBI
12	Alarcon-Vargas D and Ronai Z: SUMO in cancer-wrestlers wanted. Cancer Biol Ther. 1:237–242. 2002. View Article : Google Scholar : PubMed/NCBI
13	Mo YY, Yu Y, Theodosiou E, Ee PR and Beck WT: A role for Ubc9 in tumorigenesis. Oncogene. 24:2677–2683. 2005. View Article : Google Scholar : PubMed/NCBI
14	Zhu S, Sachdeva M, Wu F, Lu Z and Mo YY: Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene. 29:1763–1772. 2010. View Article : Google Scholar :
15	Liu Lm, Yan Mg, Yang Dh, Sun WW and Zhang JX: PIAS3 expression in human gastric carcinoma and its adjacent non-tumor tissues. Clin Res Hepatol Gastroenterol. 35:393–398. 2011. View Article : Google Scholar : PubMed/NCBI
16	Okumura F, Matsunaga Y, Katayama Y, Nakayama KI and Hatakeyama S: TRIM8 modulates STAT3 activity through negative regulation of PIAS3. J Cell Sci. 123:2238–2245. 2010. View Article : Google Scholar : PubMed/NCBI
17	Li H, Gao H, Bijukchhe SM, Wang Y and Li T: PIAS3 may represent a potential biomarker for diagnosis and therapeutic of human colorectal cancer. Med Hypotheses. 81:1151–1154. 2013. View Article : Google Scholar : PubMed/NCBI
18	Stehmeier P and Muller S: Regulation of p53 family members by the ubiquitin-like SUMO system. DNA Repair (Amst). 8:491–498. 2009. View Article : Google Scholar
19	Palvimo JJ: PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription. Biochem Soc Trans. 35:1405–1408. 2007. View Article : Google Scholar : PubMed/NCBI
20	Jackson PK: A new RING for SUMO: Wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev. 15:3053–3058. 2001. View Article : Google Scholar : PubMed/NCBI
21	Wang W, Chen Y, Wang S, Hu N, Cao Z, Wang W, Tong T and Zhang X: PIASxα ligase enhances SUMO1 modification of PTEN protein as a SUMO E3 ligase. J Biol Chem. 289:3217–3230. 2014. View Article : Google Scholar :
22	Hunter T and Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell. 79:573–582. 1994. View Article : Google Scholar : PubMed/NCBI
23	Sherr CJ: G1 phase progression: Cycling on cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
24	Association WM: World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. Bulletin of the World Health Organization. 79:3732001.
25	Neuveut C, Low KG, Maldarelli F, Schmitt I, Majone F, Grassmann R and Jeang KT: Human T-cell leukemia virus type 1 Tax and cell cycle progression: Role of cyclin D-cdk and p110Rb. Mol Cell Biol. 18:3620–3632. 1998. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
27	Klampfer L: Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets. 6:107–121. 2006. View Article : Google Scholar : PubMed/NCBI
28	Klampfer L: The role of signal transducers and activators of transcription in colon cancer. Front Biosci. 13:2888–2899. 2008. View Article : Google Scholar
29	Valentino L and Pierre J: JAK/STAT signal transduction: Regulators and implication in hematological malignancies. Biochem Pharmacol. 71:713–721. 2006. View Article : Google Scholar : PubMed/NCBI
30	Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP and Hay RT: SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18:6455–6461. 1999. View Article : Google Scholar : PubMed/NCBI
31	Shinbo Y, Niki T, Taira T, Ooe H, Takahashi-Niki K, Maita C, Seino C, Iguchi-Ariga SM and Ariga H: Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death Differ. 13:96–108. 2006. View Article : Google Scholar